A DIRECT COMPARISON OF THUNDER™ ASSAY PERFORMANCE WITH TWO EXISTING TR-FRET PLATFORMS
We compared head- to-head the performance of THUNDER™ with two existing TR-FRET assay technologies. Six endogenous phosphorylated proteins were measured in lysates from cells treated with pathway-specific modulators.
THUNDER™ phospho-protein assays exhibit superior or comparable performance at a lower cost per well.
Bioauxilium has recently introduced THUNDER™, a new immunoassay platform based on an enhanced TR-FRET technology. The THUNDER™ Cell Signaling Assay Kits are designed to measure endogenous levels of specific intracellular phosphorylated proteins with high sensitivity, specificity, robustness and cost effectiveness. The aim of this Application Note was to compare head-to-head the performance of THUNDER™ in 384-well plate format with two existing TR-FRET technologies (Companies A and B) measuring a panel of six phosphorylated proteins. The three TR-FRET assay technology
platforms were evaluated for their capacity to measure relative levels of phosphorylated 4EBP1 (T37/T46), AKTpan (S473), ERK1/2 (T202/ Y204) p38αβγ (T180/Y182), SLP-76 (S376) and STAT3 (Y705) in wholecell lysates from cells treated with pathway-specific modulators.